jurpsy schreef op 22 november 2016 09:47:
[...]
In November 2016, one of the Group’s principal competitors, Shire, announced to its patients and physicians
that it is unable to supply its plasma-derived C1 inhibitor product Cinryze® for prophylaxis of HAE, because of
a production issue at its supplier Sanquin in the Netherlands. This shortage of supply is expected by Shire to
be rectified by early 2017. At the current time, RUCONEST® is the only alternate product with published data
showing good efficacy in prophylaxis although it has not yet obtained approval for the indication in the USA,
and it may be that some physicians feel it is a suitable alternative for patients unable to obtain their supply of
Cinryze®. It is too early to say whether this will improve sales of RUCONEST® but this may be the outcome of
this situation, in which case the financial and trading position of the Group would be improved.